AST
EstablishedAST is a liver enzyme now mainly interpreted as part of the FIB-4 fibrosis risk score rather than alone.
AST is a liver enzyme that rises when liver cells are damaged. Rather than looking at AST alone, doctors now combine it with ALT, age, and platelet count (the FIB-4 score) to estimate how much liver scarring (fibrosis) a patient may have.
Aspartate aminotransferase (AST) is an enzyme released from damaged liver cells (and also heart and muscle tissue), historically used alongside ALT as a general marker of hepatocellular injury.
Elevated AST suggests liver cell injury from viral hepatitis, alcohol use, fatty liver disease, or other hepatotoxic processes; an AST/ALT ratio >2 classically suggests alcoholic liver disease. AST is rarely interpreted alone in modern practice.
Modern practice folds AST into the FIB-4 index (age + AST + ALT + platelet count), which AASLD, AGA, and the American Diabetes Association all recommend as first-line, noninvasive liver fibrosis risk stratification, replacing isolated enzyme interpretation.
FIB-4 <1.3 signals low fibrosis risk; >2.67 signals high risk warranting specialist referral and possible elastography; the indeterminate middle zone requires further noninvasive testing before biopsy consideration.
A core input into FIB-4, the first-line noninvasive liver fibrosis assessment recommended by major hepatology societies.
- Raleigh Health & Wellness Center. (2026). Understanding the Fibrosis-4 (FIB-4) Index for Liver Fibrosis.
- Dong, B., Chen, Y., Lyu, G., & Yang, X. (2022). APRI and FIB-4 for Detecting Liver Fibrosis in Autoimmune Hepatitis. Frontiers in Immunology.